Necrotising Pneumonia, Staphylococcus Aureus and Panton-Valentine Leukocidin
Author(s) -
Brendan McGrath,
Fionna Rutledge,
Emma Broadfield
Publication year - 2008
Publication title -
journal of the intensive care society
Language(s) - English
Resource type - Journals
eISSN - 2057-360X
pISSN - 1751-1437
DOI - 10.1177/175114370800900216
Subject(s) - leukocidin , staphylococcus aureus , panton–valentine leukocidin , pneumonia , microbiology and biotechnology , medicine , staphylococcal skin infections , meticillin , methicillin resistant staphylococcus aureus , incidence (geometry) , biology , bacteria , physics , optics , genetics
The Panton-Valentin leukocidin (PVL) strain of meticillin-resistant Staphylococcus aureus (MRSA) is producing a new pattern of MRSA-related disease in the UK and world-wide. PVL is one of several extracellular cytotoxins produced by Staphylococcus aureus, and is usually associated with skin and soft tissue infections. PVL MRSA is uncommon in hospitals, but in the US, and now in the UK, there have been reports of severe, rapidly progressive, community-acquired haemorrhagic, necrotising pneumonia occurring in previously healthy young adults, and associated with a mortality rate of up to 75%. We review features of the pathophysiology, diagnosis and treatment of this condition, whose incidence appears to be increasing in the UK.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom